Treatment Frequency and Satisfaction in Patients With Advanced Prostate Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Copenhagen University Hospital at Herlev
ClinicalTrials.gov Identifier:
NCT01441713
First received: September 9, 2011
Last updated: December 4, 2012
Last verified: December 2012

September 9, 2011
December 4, 2012
September 2011
May 2012   (final data collection date for primary outcome measure)
Preferred treatment/control frequency for patients with advanced prostate cancer [ Time Frame: Up to 1 year ] [ Designated as safety issue: No ]

Preferred treatment frequency is assessed by patient answers to the question:

"If treatments were equally effective from a medical standpoint - How often would you then prefer to receive treatment"

Same as current
Complete list of historical versions of study NCT01441713 on ClinicalTrials.gov Archive Site
  • Treatment satisfaction [ Time Frame: Up to 1 year ] [ Designated as safety issue: No ]
    Treatment satisfaction ranging from "Very satisfied" til "Very unsatisfied" assessed by patient answers to the questionnaire
  • Side effects to treatment [ Time Frame: Up to 1 year ] [ Designated as safety issue: No ]
    Side effects to treatment assessed by patient answers to the questionnaire
  • Treatment satisfaction, preferred frequency of clinical control, and side effects after surgical castration [ Time Frame: Up to 1 year ] [ Designated as safety issue: No ]
    As a secondary endpoint the investigators will look at answers to satisfaction, wishes for control visits and side effects in the group of patients who received surgical castration for their advanced prostate cancer.
Same as current
Not Provided
Not Provided
 
Treatment Frequency and Satisfaction in Patients With Advanced Prostate Cancer
Treatment Frequency and Satisfaction in Patients With Advanced Prostate Cancer

Patients with advanced prostate cancer usually receive some kind of pharmaceutical castration or undergo surgical castration. At the investigators department the pharmaceutical treatment is most often given with a 3 month interval.

Over the last few years new drugs, which allow for lees frequent treatment, have been developed. The purpose of this study is to assess how the treatment affects patients and if our current patients would prefer to receive treatment at different intervals than they do at the present time. At the same time the investigators will assess how surgical treatment affects our patients. This will be assessed by patient questionnaires administered at our clinic.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

Men who are receiving pharmaceutical castration treatment (hormone treatment) at Herlev Hospital for advanced prostate cancer and men who have undergone surgical castration (Orchiectomy) and are in clinical control at Herlev Hospital.

Prostatic Neoplasms
Not Provided
  • Pharmaceutical group
    Patients in pharmaceutical castration treatment for advanced prostate cancer
  • Surgical group
    Patients having undergone surgical castration treatment for advanced prostate cancer
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
178
June 2012
May 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • A diagnosis of advanced prostate cancer
  • Receiving hormone manipulation treatment (pharmaceutical castration) OR having undergone surgical castration (orchiectomy)

Exclusion Criteria:

  • Inability to read/write Danish
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
NCT01441713
HeH.750.19-25
No
Copenhagen University Hospital at Herlev
Copenhagen University Hospital at Herlev
Not Provided
Principal Investigator: Mikkel Fode, MD Herlev Hospital, University of Copenhagen
Copenhagen University Hospital at Herlev
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP